Improving Biopsies using Magnetic Nanoparticles

Information

  • Research Project
  • 7097983
  • ApplicationId
    7097983
  • Core Project Number
    R43CA105742
  • Full Project Number
    5R43CA105742-02
  • Serial Number
    105742
  • FOA Number
    PA-02-25
  • Sub Project Id
  • Project Start Date
    7/20/2005 - 19 years ago
  • Project End Date
    6/30/2007 - 17 years ago
  • Program Officer Name
    WU, ROY S
  • Budget Start Date
    7/18/2006 - 18 years ago
  • Budget End Date
    6/30/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    2
  • Suffix
  • Award Notice Date
    7/18/2006 - 18 years ago
Organizations

Improving Biopsies using Magnetic Nanoparticles

[unreadable] DESCRIPTION (provided by applicant): [unreadable] In children with acute lymphomatic leukemia (ALL) and in myelodysplastic syndrome (MDS) with older patients it is extremely important to measure the minimal residual disease (MRD) to monitor the progress of chemotherapy at early stages. Such measurements determine the prognosis, efficacy, and levels of the treatment. The normal method for detection and monitoring is through bone marrow biopsies. Unfortunately, this method, which has not changed in 40 years, requires multiple biopsies to obtain sufficient samples and these must be made at periodic intervals to monitor the treatment. The efficiency and specificity of biopsies can be improved through the use of labeled magnetic nanoparticles and "smart" magnetic collection methods. These antibody-labeled magnetic nanoparticles attach to specific cancer cells in large numbers and the cells are then collected magnetically. This magnetic biopsy technique samples more serum volume requiring fewer biopsies due to the increased efficiency and specificity for particular cell types. The method may also be used for sampling metastatic lesions and may be extended to solid tumors. Following these procedures, magnetic nanoparticles coated with anti-cancer agents may be magnetically concentrated, resulting in direct therapeutic intervention at the cancer site. [unreadable] [unreadable]

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    194560
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:194560\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SENIOR SCIENTIFIC
  • Organization Department
  • Organization DUNS
    072409886
  • Organization City
    ALBUQUERQUE
  • Organization State
    NM
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    87111
  • Organization District
    UNITED STATES